Quick answer

Mild gastrointestinal symptoms can occur when starting or increasing an FDA-approved GLP-1–based medication. The key safety questions are severity, duration, hydration, ability to eat and drink, and whether warning signs are present. A common side effect can still require help when it is intense or does not go away.

Commonly reported effects

Product labels differ, but commonly reported effects include nausea, diarrhea, vomiting, constipation, abdominal pain or discomfort, indigestion, reflux or belching, fatigue, and injection-site reactions. These effects often occur during dose escalation. Follow the product-specific label and speak with the prescriber before changing the dose.

Contact the prescriber promptly

  • Nausea, vomiting, diarrhea, constipation, or stomach problems that are severe, persistent, or getting worse.
  • Reduced intake that prevents adequate fluids or balanced meals.
  • Dizziness, weakness, dark urine, or urinating much less than usual.
  • Constipation with significant pain, swelling, vomiting, or inability to pass stool or gas.
  • Repeated low blood glucose, especially when also using insulin or a sulfonylurea.
  • New mood changes or other symptoms listed in the specific medication guide.

Red flags that need urgent evaluation

Possible pancreatitis

Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, is a warning sign described in FDA prescribing information. Stop treating this as ordinary nausea and seek medical evaluation.

Possible gallbladder disease

Upper abdominal pain, fever, yellowing of the skin or eyes, or pale or clay-colored stools can signal a gallbladder problem. Rapid or substantial weight loss can also raise gallstone risk.

Severe dehydration or kidney problems

Inability to keep fluids down, no or minimal urination, fainting, confusion, rapid heartbeat, or rapid breathing can indicate severe dehydration. Gastrointestinal fluid loss has been associated with acute kidney injury in GLP-1 product labeling.

Serious allergic reaction

Swelling of the face, lips, tongue, or throat; trouble breathing or swallowing; severe rash or itching; fainting; or a very rapid heartbeat requires emergency help.

Severe low blood glucose

GLP-1–based medicines can increase hypoglycemia risk when combined with insulin or insulin secretagogues. Confusion, slurred speech, seizure, loss of consciousness, or inability to self-treat is an emergency.

Keep the medication name specific

“GLP-1” covers several products, and tirzepatide also acts at the GIP receptor. Indications, warnings, dosing schedules, and evidence are not interchangeable. Use the FDA Medication Guide and prescribing information for the exact product prescribed to you.

Investigational products do not have the same established labeling, manufacturing controls, or post-market safety information as FDA-approved medicines. PepMarket research products are not medications and are not for human use.

A useful symptom report

When calling a clinician, report the product name, dose, last dose date, recent dose changes, symptom start time, pain location, number of vomiting or diarrhea episodes, fluids and foods kept down, urine output, bowel movements, and other glucose-lowering medicines.

See Hydration While Taking a GLP-1 and Appetite Suppression vs. Inability to Eat for the next steps.